ClinicalTrials.gg
RecruitingNCT07455929YOGIAUpdated Mar 11, 2026

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

An interventional study of Yoga-based Group Intervention (YoGI) and treatment as usual (TAU) and Strength and Flexibility Training (SFT) and TAU in Psychotic Disorders and Schizophrenia Spectrum Disorders, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Psychotic Disorders with a site in Germany — 19 open to participants now, 21 under way, 4 of them phase 3. Psychotic Disorders · Germany.

Planned enrollment
42nd of 65
60 · median 85
Started
2026
with 5 others
No phase
33 of 72
13 open now
Primary completion
2027-09
later than 12 of 20 live
Registered
70th of 72
by date
Lead sponsor
9 of 72
Charite University, Berlin, Germany

Among the 72 studies in Psychotic Disorders with a site in Germany, this one is the 42nd largest by planned enrollment of the 65 interventional ones that give a count, is one of 6 that started in 2026, is one of 33 with no phase, reaches primary completion later than 12 of the 20 other live ones, and was the 70th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

19 of the 72 studies in Psychotic Disorders with a site in Germany are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Psychotic Disorders with a site in Germany, or all of them as a file.
02

Study summary

A three-arm pilot rater-blinded randomized controlled trial is conducted, comprising Yoga-based Group Intervention (YoGI + TAU) as the experimental condition, a strength and flexibility training (SFT + TAU) group, and treatment as usual (TAU). Participants in all conditions receive the respective intervention in addition to treatment as usual (TAU) in outpatient settings in Germany. The interventions are designed for patients with schizophrenia spectrum disorders. To examine feasibility, acceptability, and preliminary efficacy, self-report measures and blinded rater-based assessments are administered at baseline (T0), after 12 weeks of participation (T1), and at a 3-month follow-up (T2). Before each intervention session, acute stress (general stress and symptom-related distress) is measured using a visual analogue scale. After each intervention session, acute stress (general stress and symptom-related distress; visual analogue scale), perceived effort (BORG-RPE-Scale), and the occurrence of unpleasant experiences are recorded via self-report, while instructors rate exercise performance and overall participation quality. In addition, semi-structured interviews are conducted at T0 and T1 to assess subjective mechanisms of change and relevant processes.

The primary outcomes of this trial are the feasibility and acceptability of YoGI and the SFT, assessed through recruitment and retention rates, adherence, and participant feedback. Based on recommendations for pilot studies of 20-50 participants, a conservative target sample size of 60 patients was determined. Further, the trial will evaluate secondary outcomes, including (body) mindfulness (SMQ, BMQ), symptoms of depression, anxiety, and stress (DASS, CDSS), positive and negative symptomatology (PANSS), psychological flexibility (CFQ), psychological well-being (WHO-QoL-BREF), social functioning (PSP), subjectively perceived cognitive functioning (SSTICS), and physical activity (SIMPAQ). This study aims to provide preliminary evidence for the efficacy of YoGI in comparison to both SFT and a TAU, and to establish a foundation for a future fully powered randomized controlled trial.

Read the detailed description

Patients are recruited across Berlin through psychiatric outpatient departments, the outpatient clinics of Charité, and social media. Recruitment occurs either through direct approach by psychologists or psychotherapists in training, or via informational posters and flyers. At baseline, eligibility screening is conducted by a blinded psychologist who is independent of the intervention delivery. This psychologist introduces the study, obtains electronic informed consent, and administers the self-report and clinician-rated assessments.

Given the behavioral nature of the interventions, participants and therapists are informed about group allocation after randomization. Randomization is performed using an Excel-generated list with block randomization (block size = 4).

Data management adheres to standard data protection procedures, including the use of anonymized identification codes and secure storage in an online database accessible only to authorized research team members. Participants retain the right to access their data and to request its deletion at any time. Upon completion of the study, each participant will receive compensation of 50 €.

03

Conditions studied

  • Psychotic Disorders
  • Schizophrenia Spectrum Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Schizophrenia Spectrum Disorder by previous (medical) reports according to ICD-10/
  • Treated as psychiatric outpatients
  • Age between 18 and 65 years
  • Ability to give
  • Willingness and ability to engage in psychotherapeutic group therapy
  • Low to moderate psychotic state indicated with a score of ≤ 6 for each item at the Positive scale of the Positive and Negative Syndrome Scale (PANSS, Peralta \& Cuesta, 1994)

Exclusion criteria

Exclusion Criteria:

  • Neurological disorders and history of severe traumatic brain injury in the past that may affect cognitive functioning
  • Acute substance dependence, excluding nicotine and prescribed medication
  • PANSS-P score on one item > 6 (= very severe)
  • Ineligibility for group participation
  • Acute suicidality, indicated by a score > 1 on item 8 of the Calgary Depression Scale for Schizophrenia (Addington, Addington, Maticka-Tyndale, \& Joyce, 1992)
  • Conflicting co-therapy such as electroconvulsive therapy or ketamine treatment as well as intensive psychotherapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental: Yoga-based Group Intervention (YoGI)

    It combines breathing exercises (pranayama), sitting, standing and lying positions (asanas), as well as relaxation techniques (shavasana). Participation is also possible from a chair, thereby ensuring accessibility for all patients, irrespective of their physical condition. The 50-minute Yoga-based Group Intervention sessions are conducted once a week over a period of 12 weeks by psychologists or psychotherapists in training who have obtained supplementary certification in yoga therapy. Additionally, study participants receive the standard outpatient care (TAU) provided in Germany.

    Behavioral: Yoga-based Group Intervention (YoGI) and treatment as usual (TAU)

  • Active comparator
    Active Comparator: Strength and Flexibility Training (SFT) and TAU

    The SFT intervention is delivered once weekly over a 12-week period. Each 50-minute group session comprises a brief warm-up with mobilization and preparatory exercises, a main phase focused on full-body strengthening and flexibility exercises, and a concluding stretching segment. Participation is also possible from a chair, thereby ensuring accessibility for all patients, irrespective of their physical condition. Sessions are conducted by qualified psychologists or psychotherapists in training in a designated sports facility. The SFT sessions are designed by a psychotherapist in training who has obtained supplementary certification in yoga therapy together with sport therapists.

    Behavioral: Strength and Flexibility Training (SFT) and TAU

  • No intervention
    No Intervention: Treatment as usual

    Participants assigned to this group receive treatment as usual (TAU) for 12 weeks. During this period, there is no contact, except for a follow-up at 8 weeks to inform them about the next steps for T1.

Interventions

  • BehavioralYoga-based Group Intervention (YoGI) and treatment as usual (TAU)

    YoGI combines breathing exercises (pranayama), sitting, standing and lying positions (asanas), as well as relaxation techniques (shavasana). Participation is also possible from a chair, thereby ensuring accessibility for all patients, irrespective of their physical condition. The 50-minute Yoga-based Group Intervention sessions are conducted once a week over a period of 12 weeks by psychologists or psychotherapists in training who have obtained supplementary certification in yoga therapy. Additionally, study participants receive the standard outpatient care (TAU) provided in Germany.

  • BehavioralStrength and Flexibility Training (SFT) and TAU

    The SFT intervention is delivered once weekly over a 12-week period. Each 50-minute group session comprises a brief warm-up with mobilization and preparatory exercises, a main phase focused on full-body strengthening and flexibility exercises, and a concluding stretching segment. Participation is also possible from a chair, thereby ensuring accessibility for all patients, irrespective of their physical condition. Sessions are conducted by qualified psychologists or psychotherapists in training in a designated sports facility. The SFT sessions are designed by a psychotherapist in training who has obtained supplementary certification in yoga therapy together with sport therapists.

06

What researchers measure

Primary outcomes

  1. Proportion of participants receiving threshold dose (Acceptability)

    The proportions of participants receiving a threshold dose of the intervention (50% or more) and the proportion of participants with outcome measures at post-intervention and data completion. (Adherence and retention rate)

    Time frame: 18 months

  2. Nr. of participants willing to participate in YoGI (Operational Feasibility)

    The number of eligible participants that are willing to participate in YoGI (recruitment)

    Time frame: 18 months

Secondary outcomes

  1. PANSS Symptomatology - Positive and Negative Symptoms

    Positive Symptoms as measure by the Positive and Negative Syndrome Scale (PANSS) to assess symptoms on a scale from 1 (non-existent) to 7 (extremely severe, 14 questions)

    Time frame: 18 months

  2. SMQ Mindfulness

    Southampton mindfulness questionnaire (SMQ), 16 items on a scale from 1 (applies fully) to 7 (does not apply at all)

    Time frame: 18 months

  3. BMQ Body Mindfulness

    Body Mindfulness Questionnaire (BMQ), 14 items on a scale from 1 (not at all) to (5) every day.

    Time frame: 18 months

  4. DASS Symptoms - Depression and Anxiety

    Depression Anxiety Stress Scales (DASS), 21 questions that can be answered on a scale from 0 (does not apply to me) to 3 (applies to me strongly/most of the time

    Time frame: 18 months

  5. CDSS Calgary Depression Scale for Schizophrenia

    Calgary Depression Scale for Schizophrenia (CDSS), 9 items assessing depressive symptoms in schizophrenia, designed to minimize overlap with negative symptoms commonly observed in schizophrenia; each item rated on a scale from 0 (absent) to 3 (severe).

    Time frame: 18 months

  6. PSP Personal and Social Performance

    Personal and Social Performance Scale (PSP), Interview measures personal and social functioning in the domains of: Socially useful activities (eg. work and study), Personal and social relationships, Self-care, Disturbing and aggressive behaviors. The scale compromises four domains/items rated on a scale from absent to highly severe.

    Time frame: 18 months

  7. CFQ Cognitive Fusion

    Cognitive Fusion Questionnaire (CFQ), 7 questions that can be answered on a scale from 1(not applicable) to 7 (applies always)

    Time frame: 18 months

  8. WHO-QOL-Bref Quality of Life - domains assessed include physical and psychological health, social relationships and environment

    World Health Organisation Quality of Life (WHO-QOL-Bref) to assess quality of life measured on a scale from 1 (never) to 5 (always). Facets incorporated in the 4 domains: 1. Physical health - Activities of daily living, Dependence on medicinal substances and medical aids, Energy and fatigue, Mobility Pain and discomfort, Sleep and rest, Work Capacity; 2. Psychological - Bodily image and appearance, Negative feelings, Positive feelings, Self-esteem, Spirituality / Religion / Personal beliefs, Thinking, learning, memory and concentration; 3. Social relationships - Personal relationships Social support, Sexual activity; 4. Environment - Financial resources, Freedom, physical safety and security, Health and social care: accessibility and quality, Home environment, Opportunities for acquiring new information and skills, Participation in and opportunities for recreation / leisure activities, Physical environment (pollution / noise / traffic / climate), Transport

    Time frame: 18 months

  9. SSTICS Subjective Scale to Investigate Cognition in Schizophrenia

    Simple Physical Activity Questionnaire (SIMPAQ), 5 items assessing physical activity and sedentary behavior in populations with severe mental illness. Covers time spent in bed, sedentary time, walking, structured exercise, and incidental activity. Responses are reported in minutes per day over the past seven days.

    Time frame: 18 months

  10. Visual Analogue Scales ("Bubbles")

    Visual Analogue Scale with 'Bubbles', 4 self-report items represented by bubbles of increasing size, indicating different levels of general stress and symptom-related distress.

    Time frame: During the intervention (12 weeks)

  11. BORG-RPE-Scale

    Self-report rating scale of perceived exertion that quantifies the subjective intensity of physical effort during activity. The scale ranges from 6 ("no exertion") to 20 ("maximal exertion").

    Time frame: During the intervention (12 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tobelmann L, Hahne I, Schulze T, Bergmann N, Fuchs L, Zierhut M, Hahn E, Boge K. Mechanisms of action and processes of yoga-based group intervention for inpatients with schizophrenia spectrum disorders-A longitudinal qualitative study. Front Psychiatry. 2023 Feb 7;14:1086468. doi: 10.3389/fpsyt.2023.1086468. eCollection 2023. PubMed 36824673 ↗
  • Hahne I, Zierhut M, Bergmann N, Hahn E, Ta TMT, Calvano C, Bajbouj M, Boge K. Yoga-Based Group Intervention for Inpatients with Schizophrenia Spectrum Disorders-Feasibility, Acceptability, and Preliminary Outcomes of a Rater-Blinded Randomized Controlled Trial. Schizophr Bull. 2026 Jan 16;52(1):sbae198. doi: 10.1093/schbul/sbae198. PubMed 39550215 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2027, 18 months later.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 18 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 6, 2026
StartEst.
Mar 2026
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2028
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07455929
Responsible party
Kerem Böge (Prof. Dr. Dr., Charite University, Berlin, Germany) — Principal investigator
First posted
Mar 6, 2026
Start date
Mar 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 11, 2026

Study contacts

Kerem Böge, Prof. Dr. Dr.
Contact
kerem.boege@charite.de
+4930450517319

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion